GlassScriptPhysician profile
Kristofer Michael Dosh
NPI 1790999092
$8,835.49
in general payments reported to CMS, 2019-2025
20 companies · $2,947 in 2025
The $2,947 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $388 · 2021: $1,826 · 2022: $365 · 2023: $605 · 2024: $1,906 · 2025: $2,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,303 · Food and Beverage: $2,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,303.10 |
| Food and Beverage | $2,154.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,541.30 | 2020-2025 | General - Vascular Access, Watchman Flx, Avvigo Guidance System |
| Edwards Lifesciences Corporation | $1,594.97 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,567.97 | 2021 | |
| Medtronic Vascular, INC. | $316.90 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.51 | 2019-2025 | Lifevest |
| Medtronic, INC. | $221.40 | 2021-2025 | Corevalve Evolut R, Hawkone |
| Astrazeneca Pharmaceuticals LP | $214.99 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $207.02 | 2019-2023 | |
| Philips North America LLC | $168.20 | 2022-2024 | (Az7) Lasers |
| Abiomed | $162.63 | 2023-2024 | Impella |
| Cardiovascular Systems INC. | $154.89 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $128.30 | 2019 | |
| Surmodics, INC. | $79.70 | 2023-2025 | Pounce LP Thrombectomy, Pounce Thrombectomy, Pounce Venous Thrombectomy System |
| Amgen INC. | $76.47 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $57.44 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $52.83 | 2025 | Artix Mt |
| Pfizer INC. | $27.75 | 2020-2022 | |
| Shockwave Medical, INC | $24.35 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $11.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristofer Dosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.